Toward a cure for osteoporosis: Reversal of excessive bone fragility

Osteoporosis International

Volumn 2, Issue 1, 1991, Pages 12-19

  Turner, C H ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Estrogen; Liposomes; Prostaglandin E2

Indexed keywords

BONE REMODELING; DRUG EFFECT; DRUG THERAPY; FORECASTING; HUMAN; OSTEOPOROSIS; REVIEW;

BONE REMODELING; DRUG THERAPY; FORECASTING; HUMAN; OSTEOPOROSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026231220     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/BF01627073     Document Type: Review

References (99)

1. Relative risk of fall severity, body habitus and bone density in hip fracture among the elderly
2. The effect of supplemental oral phosphate on the bone mineral changes during prolonged bed rest
3. Effect of prolonged bed rest on bone mineral
4. Bone mass and osteoporotic fractures (editorial)
5. Changes in resorption spaces in femoral cortical bone with age
6. Influence of maturation and aging on mechanical and biochemical parameters of rat bone
7. Aging of bone tissue: mechanical properties
8. Factors of safety in the structure of mammals
9. Scaling body support in mammals: limb posture and muscle mechanics
10. Dynamic strain similarity in vertbrates: an alternative to allometric limb bone scaling
11. Age-related structural changes in trabecular and cortical bone: cellular mechanisms and biomechanical consequences
12. Star volume of marrow space and trabeculae of the first lumbar vertebra: sampling efficiency and biological variation
13. Involutional osteoporosis
14. Calcitonin: physiology and pathophysiology
15. The pathobiology of the osteoclast
16. Experimental osteoporosis and parathyroid activity
17. A unified concept of osteoporosis (editorial)
18. Two modes of action of the bisphosphonates on osteoclastic resorption of mineralized matrix
19. Temporal relationships between bone loss and increased bone turnover in ovariectomized rats
20. Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats
21. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells
22. Evidence of estrogen receptors in normal human osteoblast-like cells
23. Long-term calcitonin therapy in postmenopausal osteoporosis
24. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
25. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
26. Bisphosphonate effects on alveolar bone during rat molar drifting
27. On the dependence of the elasticity and strength of cancellous bone on apparent density
28. Compressive mechanical properties and the distribution of density and porosity in the human femur
29. Limb mechanics as a function of speed and gait: a study of functional strains in the radius and tibia of horse and dog
30. The structural contribution of cortical and trabecular bone in the femoral neck
31. Stress redistribution of osteoporotic spine
32. The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae
33. Fracture risk: a role for compact bone (letter)
34. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
35. The skeletal changes of chronic experimental fluorosis
36. Mechanism of acute lower extremity pain syndrome in fluoride-treatment osteoporotic patients
37. Fluoride therapy for vertebral crush fracture syndrome: status report
38. Fluoride pharmokinetics: its implications in the fluoride treatment of osteoporosis
39. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures
40. Effect of growth hormone on skeletal mass in adult dogs
41. Growth hormone: the effect on skeletal renewal in the adult dog. I. Morphometric studies
42. Growth hormone: the effect on skeletal renewal in the adult dog. II. Mineral kinetic studies
43. Effects of growth hormone in osteoporosis
44. On an attempt to treat primary and secondary osteoporosis with human growth hormone
45. Growth hormone in osteoporosis
46. Impaired growth hormone secretion in the adult population
47. Insulin-like growth factors I and II: aging and bone density in women
48. Effects of human growth hormone in men over 60 years old
49. Effects of repetitive administration of growth hormone-releasing hormone on growth hormone secretion, insulin-like growth factor I, and bone metabolism in postmenopausal women
50. Bone aging
51. Age-dependent decline in extracellular matrix-induced local bone differentiation
52. Growth hormone dependent matrix-induced heterotopic bone formation
53. Postmenopausal osteoporosis: its clinical features
54. Prevention of spinal osteoporosis in oophorectomised women
55. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy
56. Comparative metabolic study of percutaneous versus oral micronized 17 β-oestradiol in replacement therapy
57. Biological and endocrine aspects of transdermal 17β-oestradiol administration in post-menopausal women
58. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after subcutaneous hormone implants
59. Bone mineral density after resumption of menses in amenorrheic women
60. Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat
61. Progesterone as a bone-tropic hormone
62. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action
63. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass
64. Changes in body composition following therapy of osteoporosis with methandrostenolone
65. Anabolic steroids and osteoporosis
66. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis
67. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
68. The effects of nandrolone decanoate on rarefying bone tissue
69. Effecti ossei della terapia con nandrolone decanoato nella osteoporosi postmenopausale
70. Prostaglandins: stimulation of bone resorption in tissue culture
71. Complement-dependent stimulation of prostaglandin synthesis and bone resorption
72. Stimulation of bone formation by prostaglandins E2
73. Transient effects of subcutaneously administered prostaglandin E2 on cancellous and cortical bone in young adult dogs
74. Effects of PGE2 on production of new cancellous bone in the axial skeleton of ovariectomized rats
75. PGE2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats
76. Bone formation induced in an infant by systemic prostaglandin-E2 administration
77. Stimulation of bone formation in vivo by transforming growth factor-β: remodeling of woven bone and lack of inhibition by indomethacin
78. In vivo effects of human recombinant transforming growth factor β on bone turnover in normal mice
79. In vivo stimulation of bone formation by transforming growth factor-β
80. Targeted drug delivery
81. Use of liposomes as injectable-drug delivery systems
82. Non-collagen proteins in bone
83. In vitro and in vivo antagonists against parathyroid hromone-related protein
84. New methods of drug delivery
85. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related maglignacies?
86. Treatment of osteoporoses by manipulation of coherent bone cell populations
87. The ADFR concept revisited
88. Preliminary observations of a form of coherence therapy for osteoporosis
89. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study
90. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (l–38) hPTH and diphosphonate EHDP: protocol of study I, osteoporosis trial Hannover
91. Effects of activate-depress-free-repeat (ADFR) treatment on bone mass in old beagles with osteoporosis
92. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin
93. Role of TGFβ in bone remodeling